Our solution

This picture is illustrating the development of a disease-modifying osteoarthritis drug

A first-in-
class
medicine

4P004 is a novel first-in-class drug candidate addressing a high unmet medical need that is the absence of a curative treatment for osteoarthritis.

About 4P004

Through the development of 4P004, we hope to bring a solution to improve quality of life for the millions of people suffering from osteoarthritis worldwide.

4P004 is a disease-modifying OA drug (DMOAD) candidate

4P004 is a breakthrough innovation in osteoarthritis

4P004 has shown its potential to modify the course of the disease preclinically

Our solution milestones

4Moving Biotech will conduct a Phase I on OA patients in Q1 2022.

4P004

Preclinical

Phase 1

Learn more

Phase 2

Phase 3

4P004

Phase 1

Learn more

4P004, triple action

Figure illustrating the disease modifying osteoarthritis drug called 4P004

Made with

We have developed 4P004, a Disease Modifying OsteoArthritis Drug (DMOAD) candidate.

We have preclinically demonstrated that 4P004 has a unique triple effect: anti-pain, anti-inflammatory and cartilage protection/regeneration.

Figure illustrating the osteoarthritis anti-inflammatory and anti-pain benefits enabled by the 4P004 treatment

Made with

Anti-inflammatory: Under OA inflammatory conditions, joint tissues secrete cytokines and degradative enzymes involved in joint cartilage destruction.

Anti-pain: 4P004 has demonstrated in preclinical OA models, analgesic effects in parallel with a decrease of inflammatory markers.

Figure illustrating the protection and regeneration of the cartillage thanks to the 4P004 treatment

Made with

Cartilage protection/regeneration: 4P004 blocks the expression of degradative enzymes. In an experimental OA surgical model, 4P004 increases medial cartilage repair. Moreover, 4P004 increases the number of proliferating chondrocytes clusters, revealing not only a decrease in cartilage degradation, but also cartilage regeneration